iPS Cells & Regenerative Medicine– category –
-
Avaí Bio Achieves GMP Milestone for Anti-Aging Cell Therapy; Beam Therapeutics Targets Accelerated Approval for BEAM-302; Sana Partners with Mayo Clinic for Type 1 Diabetes
Newswire.ca Canada Overview Multiple biotech companies reported significant advancements: Avaí Bio completed its GMP-grade Master Cell Bank (MCB) for the α-Klotho anti-aging program, paving the way for preclinical and clinical trials. Be... -
Sana Biotechnology to Initiate Hypoimmune Cell Therapy and In Vivo CAR T Trials This Year, with Data Expected Within 12 Months
TradingView USA Overview Sana Biotechnology is set to commence clinical trials for two key platforms this year: a hypoimmune cell therapy targeting Type 1 diabetes and an in vivo CAR T platform for oncology and autoimmune diseases. Initi... -
Made Scientific and Pluristyx Announce Integrated iPSC Development & Manufacturing Partnership to Accelerate Next-Generation iPSC-Derived Cell Therapies
PR Newswire USA Overview Made Scientific, a cell therapy CDMO, and Pluristyx, an iPSC platform technology provider, announced an integrated iPSC development and manufacturing partnership. This collaboration aims to accelerate the clinica... -
Fate Therapeutics Presents FT819/FT839 Data at EULAR 2026: Rapid, Sustained Improvement and Favorable Safety Profile in SLE Patients
GlobeNewswire (Fate Therapeutics Press Release) USA Overview Fate Therapeutics presented data from its off-the-shelf CAR T-cell programs, FT819 and FT839, at the 2026 European Congress of Rheumatology (EULAR) Annual Meeting. FT819 demons... -
Cynata Therapeutics to Announce Phase 3 iPSC-Derived MSC Results for Knee Osteoarthritis in June; Acute GVHD Phase 2 Nears Completion
Regen Report Australia Overview Cynata Therapeutics is set to release top-line results from its Phase 3 clinical trial, 'STOP-OA,' for knee osteoarthritis (KOA) using iPSC-derived mesenchymal stem cells (iPSC-MSC). The KOA trial database... -
Intellia Therapeutics Sees Steady Progress with HAE Therapy Lonvo-Z and ATTR Amyloidosis Therapy Nex-Z; FDA Lifts Clinical Hold on Nex-Z
Seeking Alpha USA Overview Intellia Therapeutics has demonstrated steady progress in the clinical development of Lonvo-Z for hereditary angioedema (HAE) and Nex-Z for ATTR amyloidosis. Positive data reported from the Phase 3 HAELO study ... -
FDA Issues New Draft Guidance to Accelerate Cell and Gene Therapy Development: Promoting Efficiency Through Prior Knowledge Utilization
FDA Press Announcements USA Overview The FDA announced new draft guidance on June 2, 2026, aimed at accelerating the development of cell and gene therapies. This guidance encourages sponsors to effectively leverage 'prior knowledge,' par... -
Century Therapeutics to Present iPSC-Derived CNTY-813 (Featuring Allo-Evasion™ 5.0) for Type 1 Diabetes at ADA 86th Scientific Sessions
Benzinga USA Overview Century Therapeutics is scheduled to deliver an oral presentation on its innovative iPSC-derived islet cell replacement therapy, CNTY-813, for Type 1 diabetes at the American Diabetes Association (ADA) 86th Scientif... -
REPROCELL Unveils AI-Designed CRISPR for Hypoimmune iPSC Engineering, Accelerating Off-the-Shelf Cell Therapy Development
REPROCELL Japan Overview REPROCELL announced that its StemEdit platform, integrating AI-designed CRISPR with optimized workflows, has achieved high gene-editing efficiency and reduced off-target activity in induced pluripotent stem cells... -
Japan Nears Approval of BioCardia’s CardiAMP Heart Failure Cell Therapy: PMDA Issues Consultation Record Supporting Regulatory Submission
Longevity.Technology Japan Overview Japan has moved closer to approving BioCardia's CardiAMP cell therapy for ischemic heart failure with reduced ejection fraction (HFrEF). Japan's Pharmaceuticals and Medical Devices Agency (PMDA) issued...
